Immunic, Inc. (IMUX)
7.79
-0.33
(-4.06%)
USD |
NASDAQ |
Nov 12, 16:00
7.79
0.00 (0.00%)
After-Hours: 20:00
Immunic Free Cash Flow (Quarterly) : -31.25M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -31.25M |
| March 31, 2026 | -17.30M |
| December 31, 2025 | -19.29M |
| September 30, 2025 | -20.21M |
| June 30, 2025 | -24.64M |
| March 31, 2025 | -21.82M |
| December 31, 2024 | -22.97M |
| September 30, 2024 | -20.85M |
| June 30, 2024 | -17.21M |
| March 31, 2024 | -24.00M |
| December 31, 2023 | -14.19M |
| September 30, 2023 | -17.36M |
| June 30, 2023 | -20.00M |
| March 31, 2023 | -19.62M |
| December 31, 2022 | -15.10M |
| September 30, 2022 | -13.67M |
| June 30, 2022 | -15.79M |
| March 31, 2022 | -20.69M |
| December 31, 2021 | -23.70M |
| September 30, 2021 | -17.62M |
| June 30, 2021 | -29.02M |
| March 31, 2021 | -12.96M |
| December 31, 2020 | -13.99M |
| September 30, 2020 | -11.97M |
| June 30, 2020 | -9.282M |
| Date | Value |
|---|---|
| March 31, 2020 | -11.03M |
| December 31, 2019 | -6.56M |
| September 30, 2019 | -5.989M |
| June 30, 2019 | -11.00M |
| March 31, 2019 | -5.324M |
| December 31, 2018 | -3.465M |
| September 30, 2018 | -2.09M |
| June 30, 2018 | 9.009M |
| March 31, 2018 | -13.22M |
| December 31, 2017 | -10.03M |
| September 30, 2017 | -9.586M |
| June 30, 2017 | -10.28M |
| March 31, 2017 | -11.18M |
| December 31, 2016 | -9.221M |
| September 30, 2016 | -8.161M |
| June 30, 2016 | -8.867M |
| March 31, 2016 | -10.08M |
| December 31, 2015 | -9.339M |
| September 30, 2015 | -12.35M |
| June 30, 2015 | -16.42M |
| March 31, 2015 | -14.18M |
| December 31, 2014 | -10.44M |
| September 30, 2014 | -11.51M |
| June 30, 2014 | -10.11M |
| March 31, 2014 | -10.17M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 10.26M |
| Sionna Therapeutics, Inc. | -18.72M |
| Alnylam Pharmaceuticals, Inc. | 271.15M |
| Anika Therapeutics, Inc. | 6.716M |
| Savara, Inc. | -42.82M |